Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of VLPCOV-05 booster vaccine for prevention of COVID-19 in adults
jRCT2031240751Phase 3Active, not recruiting
- Sponsor
- VLP Therapeutics Japan
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of VLPCOV-05 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by VLP Therapeutics Japan. Primary endpoint: COVID-19 incidence rate during the evaluation period. Started Apr 2025; status: active, not recruiting.
02
Drugs
VLPCOV-05
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031240751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240751.